Vaccine strategies for cancer immunotherapy depend on the induction of dendritic cells (DC) in close proximity to T cells. This is best accomplished in lymphoid tissue. However, directing vaccines to lymphoid tissue has been quite challenging. Continue reading
Tag Archives: PSMA
Targeted Nanoparticles for Cancer – optimizing physiochemical properties for enhanced tumor-killing
Last week, BIND Therapeutics and Amgen ended a collaboration on a targeted nanaoparticle that employed a proprietary cytotoxic compound from Amgen. However, BIND has several other programs (and partnerships with AstraZeneca, Roche, and Pfizer) that are proceeding in the clinic, which employ its Targeted Nanoparticle (TNP) technology. How does this work? Continue reading